Lung Cancer section

Lung Cancer News & Features

No Differences in Lung Cancer Mutations Between White, Black Patients

No Differences in Lung Cancer Mutations Between White, Black Patients

Analyses of lung tumor specimens were used to determine whether mutational profiles of lung cancers differ between black and white patients. Such differences could explain differences in prognosis and lead to reductions in outcomes disparities.

Considerable Shifts in NSCLC Treatment With Modest Gains in Survival

Considerable Shifts in NSCLC Treatment With Modest Gains in Survival

Investigators report on trends in treatment of advanced-stage NSCLC from 2000 to 2011, including impact on survival and total Medicare spending.

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

Study evaluated differences in survival with respect to the time interval between tumor resection and initiation of postoperative chemotherapy in patients with NSCLC.

Comparison of Three Information Sources for Smoking Information in Electronic Health Records

Comparison of Three Information Sources for Smoking Information in Electronic Health Records

[Cancer Informatics] This research examinbed independent and joint performance of retrieving smoking status through different sources and compared the performance of retrieving smoking strength information from narrative text and PPI.

The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma

The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma

[OncoTargets and Therapy] The surgical approach that offers the best outcomes for malignant pleural mesothelioma management is still debated. This research examines the efficacy of surgical treatment.

Cisplatin-etoposide and Carboplatin-paclitaxel With RT Comparable for Stage III Lung Cancer

Cisplatin-etoposide and Carboplatin-paclitaxel With RT Comparable for Stage III Lung Cancer

Carboplatin-paclitaxel with concurrent RT has comparable efficacy with cisplatin-etoposide plus RT in patients with stage III NSCLC.

Atezolizumab Prolongs Survival vs Docetaxel in Previously Treated NSCLC

Atezolizumab Prolongs Survival vs Docetaxel in Previously Treated NSCLC

The efficacy and safety of atezolizumab in patients with previously treated NSCLC was evaluated in the OAK trial, an open-label, pivotal, phase 3 study, the results of which were recently published.

Survival Not Better With Onartuzumab Plus Erlotinib for MET-Positive NSCLC

Survival Not Better With Onartuzumab Plus Erlotinib for MET-Positive NSCLC

Results of the METLung trial are presented. In this trial, researchers evaluated the efficacy and safety of onartuzumab in patients with advanced NSCLC selected by MET immunohistochemistry.

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

A study presented at the World Conference on Lung Cancer compared progression-free survival after treatment with osimertinib with that of platinum therapy plus pemetrexed in a select group of patients with T790M-positive advanced NSCLC.

Mental Health Disorder Linked to Poorer Survival in NSCLC

Mental Health Disorder Linked to Poorer Survival in NSCLC

Among patients with non-small cell lung cancer (NSCLC), those with a mental health disorder appeared to have a higher risk of death.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs